Merrimack names Richard Peters as president and CEO
Dr. Peters will join Merrimack from his current role at Sanofi Genzyme, where he serves as Senior Vice President and Head of Global Rare Diseases.
Dr. Peters is a veteran healthcare executive with 25 years of biopharmaceutical industry experience and a proven record of building and leading organizations in diverse settings and life cycle phases: from development stage companies to large, global pharmaceutical companies.
He is an expert in the field of Oncology, previously serving as Division Medical Officer at Sanofi Oncology, and is the former Head of Global and US Medical Affairs at Genzyme Transplant/Oncology.
He has also served as a Senior Director at Onyx Pharmaceuticals, as a Director at Amgen, and as Chief Executive Officer of Mednav, a venture capital-backed healthcare information technology startup.
Dr. Peters is a Harvard-trained physician-scientist, and has served on the faculty at the Massachusetts General Hospital and completed a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School.
He is also an active founder and angel biotech investor in start-up biopharmaceutical companies.
Dr. Peters replaces Gary Crocker, Chairman and Interim President and CEO, who guided the Company during the recent restructuring process and search for a permanent CEO and will remain Chairman of the Board. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST
Good reputation can be bad for business Leadership
Kellogg to buy Rxbar for $600 million Companies